Molecular interactions of Alzheimer's Aβ protofilaments with lipid membranes

Florentina Tofoleanu1, Nicolae-Viorel Buchete

  • 1School of Physics, University College Dublin, Belfield, Dublin 4, Ireland.

Insights

Interactions between amyloid beta (Aβ) protofilaments and lipid membranes disrupt fibril structure and thin membranes. Electrostatic forces between Aβ and lipid headgroups drive these damaging interactions, impacting neurodegenerative disease pathology.

Area of Science:

  • Biophysics
  • Computational Biology
  • Neuroscience

Background:

  • Amyloid fibrils and peptide oligomers are implicated in major neurodegenerative diseases.
  • Understanding amyloid-membrane interactions is crucial for disease pathology.

Purpose of the Study:

  • Investigate molecular interactions between amyloid beta (Aβ) protofilaments and lipid bilayer membranes.
  • Elucidate the role of these interactions in fibril stability and membrane function.

Main Methods:

  • Computational modeling and all-atom molecular dynamics simulations.
  • Simulations included explicit water molecules and various protofilament-membrane orientations.

Main Results:

  • Observed significant alterations in protofilament side-chain contacts, with partial preservation of β-sheet structure.
  • Identified electrostatic interactions between Aβ charged residues (E22, D23, K28) and lipid headgroups as a major driving force.
  • Documented penetration of hydrophobic C-terminal amino acids, leading to fibril structure loss and membrane thinning.

Conclusions:

  • Membrane interactions reshape amyloid fibril structure and affect membrane integrity.
  • Electrostatic forces and hydrogen bonding are key mediators of fibril-membrane interactions.
  • Findings may inform experimental studies on amyloid fibril behavior at membrane interfaces.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...